Nanobiotix is trading at $30.03, up 5.15% in pre-market on November 4, 2026; no clear company-specific catalyst has been identified. - Its latest listed press release, dated October 24, concerns final Phase 1 melanoma study data but does not establish a cause for the move. - Supplied market context shows mixed-to-positive U.S. index futures, which do not clearly explain the gain. No volume details are available in the supplied price data.